# Sai Life Sciences (NSE: SAILIFE) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SAILIFE · Pivot · prices to 22 Oct 2026

Sai Life Sciences (NSE: SAILIFE) closed at ₹1,396.80 on 22 Oct 2026, down 0.06% on the day. With a market capitalisation of ₹29,633 Cr, it ranks 270th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.

At its last close the stock traded at 85.1× trailing earnings, against a return on equity of 8.0% in FY25. Over the past year the share price has risen 63.2%. Its 52-week range is ₹783.85 (5 Feb 2026) to ₹1,697.00 (9 Sep 2026); the last close is 17.7% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹602 Cr (+3.9% year on year) and net profit ₹104 Cr (+18.1%), on a consolidated basis. Promoters held 34.53% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,396.80 |
| Market cap | ₹29,633 Cr |
| P/E (trailing) | 85.1 |
| ROE | 8.0% (FY25) |
| ROCE | 12.5% (FY25) |
| Debt to equity | 0.06 |
| 52-week high | ₹1,697.00 (9 Sep 2026) |
| 52-week low | ₹783.85 (5 Feb 2026) |
| 1-year return | +63.2% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹602 Cr | +3.9% | ₹104 Cr | +18.1% | ₹4.93 |
| Q3 FY26 | ₹556 Cr | +26.5% | ₹100 Cr | +86.4% | ₹4.77 |
| Q2 FY26 | ₹537 Cr | +35.9% | ₹84 Cr | +102.0% | ₹4.01 |
| Q1 FY26 | ₹496 Cr | +77.5% | ₹60 Cr | — | ₹2.90 |
| Q4 FY25 | ₹580 Cr | +30.9% | ₹88 Cr | +57.3% | ₹4.24 |
| Q3 FY25 | ₹440 Cr | +14.6% | ₹54 Cr | +36.0% | ₹2.89 |
| Q2 FY25 | ₹396 Cr | — | ₹42 Cr | — | ₹2.22 |
| Q1 FY25 | ₹280 Cr | — | −₹14 Cr | — | −₹0.71 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,695 Cr | ₹170 Cr |
| FY24 | ₹1,465 Cr | ₹83 Cr |
| FY23 | ₹1,217 Cr | ₹10 Cr |
| FY22 | ₹870 Cr | ₹6 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 34.53%
- Foreign institutions: 19.65%
- Domestic institutions: 32.71%
- Non-institutions: 13.11%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Narayana Hrudayalaya](https://app.pivotnow.in/stock/NH) | ₹1,691.90 | ₹34,602 Cr | 42.4 | 17.8% |
| [Emcure Pharmaceuticals](https://app.pivotnow.in/stock/EMCURE) | ₹1,759.20 | ₹33,812 Cr | 145.1 | 18.7% |
| [Global Health](https://app.pivotnow.in/stock/MEDANTA) | ₹1,215.10 | ₹32,216 Cr | 58.9 | 14.0% |
| [Dr. Lal Path Labs](https://app.pivotnow.in/stock/LALPATHLAB) | ₹1,838.50 | ₹30,907 Cr | 58 | 20.1% |
| [Wockhardt](https://app.pivotnow.in/stock/WOCKPHARMA) | ₹1,889.60 | ₹30,150 Cr | 144.8 | 4.3% |
| [Krishna Institute of Medical Sciences](https://app.pivotnow.in/stock/KIMS) | ₹671.30 | ₹28,080 Cr | 111.9 | 18.0% |

## Questions and answers

### What is the share price of Sai Life Sciences today?

Sai Life Sciences (NSE: SAILIFE) last closed at ₹1,396.80 on 22 Oct 2026. Its 52-week high is ₹1,697.00 and its 52-week low is ₹783.85.

### What is the market cap of Sai Life Sciences?

Sai Life Sciences' market capitalisation is ₹29,633 Cr (₹29,633 Cr) at the 22 Oct 2026 close, ranking 270th among the NSE companies Pivot tracks.

### What is the P/E ratio of Sai Life Sciences?

Sai Life Sciences trades at a trailing P/E of 85.1. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 111.9.

### What is the ROE and ROCE of Sai Life Sciences?

Return on equity was 8.0% in FY25 and return on capital employed was 12.5% in FY25 (consolidated figures).

### Is Sai Life Sciences a debt-free company?

No. Sai Life Sciences' debt-to-equity ratio was 0.06 in FY25, with total debt of ₹0 Cr.

### What were Sai Life Sciences' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Sai Life Sciences reported revenue of ₹602 Cr, +3.9% year on year, and net profit of ₹104 Cr, +18.1% year on year.

### How has Sai Life Sciences stock performed over the last year?

Sai Life Sciences' share price has risen 63.2% over the past year, +11.5% over three months and −13.3% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Sai Life Sciences?

As of 30 Jun 2026: promoters 34.53%, foreign institutions 19.65%, domestic institutions 32.71%, non-institutions 13.11%.

### Who are Sai Life Sciences' competitors?

The listed Pharma & Healthcare companies closest to Sai Life Sciences by market cap are Narayana Hrudayalaya, Emcure Pharmaceuticals, Global Health, Dr. Lal Path Labs, Wockhardt and Krishna Institute of Medical Sciences.

### Is Sai Life Sciences a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Sai Life Sciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SAILIFE against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.